Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment

Liver International

Volumn 35, Issue 9, 2015, Pages 2100-2107

  Basile, Umberto ^a   Gragnani, Laura ^b   Piluso, Alessia ^b   Gulli, Francesca ^a   Urraro, Teresa ^b   Dell'Abate, Maria T ^a   Torti, Eleonora ^a   Stasi, Cristina ^b   Monti, Monica ^b   Rapaccini, Gian Ludovico ^a   Zignego, Anna Linda ^b  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Free light chains; Hepatitis C virus; Mixed cryoglobulinaemia; Rituximab

Indexed keywords

COMPLEMENT COMPONENT C4; CRYOGLOBULIN; FREE LIGHT CHAIN; IMMUNOGLOBULIN; KAPPA FREE LIGHT CHAIN; LAMBDA FREE LIGHT CHAIN; RHEUMATOID FACTOR; RITUXIMAB; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; IMMUNOGLOBULIN KAPPA CHAIN;

ADULT; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MIDDLE AGED; MIXED CRYOGLOBULINAEMIA; NEPHELOMETRY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULITIS; AGED; BLOOD; CHRONIC HEPATITIS C; COMPLICATION;

AGED; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITUXIMAB; VASCULITIS;

EID: 84939000892     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12829     Document Type: Article

References (37)

1. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117: 573-7.
2. Zignego AL, Gragnani L, Giannini C, Laffi G. The hepatitis C virus infection as a systemic disease. Intern Emerg Med 2012; 7(Suppl 3): S201-8.
3. Vallat L, Benhamou Y, Gutierrez M, et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 2004; 50: 3668-78.
4. Sansonno D, De Vita S, Iacobelli AR, et al. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998; 160: 3594-601.
5. Knight GB, Gao L, Gragnani L, et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis Rheum 2010; 62: 2152-9.
6. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia-a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40: 837-56.
7. Saccardo E, Novati P, Sironi D, et al. Causes of death in symptomatic cryoglobulinemia: 30 years of observation in a Department of Internal Medicine. Dig Liver Dis 2007; 39(Suppl 1): S52-4.
8. Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet 2012; 379: 348-60.
9. Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011; 10: 444-54.
10. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 843-53.
11. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34.
12. Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116: 335-42.
13. Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. J Natl Compr Canc Netw 2011; 9: 1146-83.
14. Bird JMOR, D'Sa S, Snowden JA, et al. Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH), UK Myeloma Forum. Guidelines for the Diagnosis and Management of Multiple Myeloma 2013. London, UK: British Committee for Standards in Haematology (BCSH), 2013.
15. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009; 147: 22-42.
16. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125: 681-700.
17. Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011; 154: 32-75.
18. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117: 4701-5.
19. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-24.
20. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-44.
21. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489-91.
22. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-7.
23. Terrier B, Sene D, Saadoun D, et al. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis 2009; 68: 89-93.
24. Geri G, Terrier B, Semoun O, et al. Surrogate markers of B cell non-Hodgkin's lymphoma in patients with hepatitis C virus-related cryoglobulinaemia vasculitis. Ann Rheum Dis 2010; 69: 2177-80.
25. Zignego AL, Giannelli F, Marrocchi ME, et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 2000; 31: 474-9.
26. Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998; 129: 294-8.
27. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
28. Gaiani S, Gramantieri L, Venturoli N, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997; 27: 979-85.
29. Stasi C, Arena U, Vizzutti F, et al. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool? Dig Liver Dis 2009; 41: 863-6.
30. Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92: 143-4.
31. Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum 2013; 43: 9-17.
32. Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res (Hoboken) 2013; 65: 648-52.
33. Fabris M, Quartuccio L, Lombardi S, et al. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 2012; 11: 315-20.
34. Gragnani L, Piluso A, Giannini C, et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum 2011; 63: 1446-51.
35. Bibas M, Lorenzini P, Cozzi-Lepri A, et al. Polyclonal serum-free light chains elevation in HIV-infected patients. AIDS 2012; 26: 2107-10.
36. Basile U, Mussap M. Rationale and prospects of serum immunoglobulin free light chain (FLC) determination in chronic inflammatory disease. Biochimica Clinica 2013; 37: 357-64.
37. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. 2014; Retrieved April 24, 2014.